Literature DB >> 20805395

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

George G Zhanel1, Melanie DeCorby, Heather Adam, Michael R Mulvey, Melissa McCracken, Philippe Lagacé-Wiens, Kimberly A Nichol, Aleksandra Wierzbowski, Patricia J Baudry, Franil Tailor, James A Karlowsky, Andrew Walkty, Frank Schweizer, Jack Johnson, Daryl J Hoban.   

Abstract

A total of 5,282 bacterial isolates obtained between 1 January and 31 December 31 2008, inclusive, from patients in 10 hospitals across Canada as part of the Canadian Ward Surveillance Study (CANWARD 2008) underwent susceptibility testing. The 10 most common organisms, representing 78.8% of all clinical specimens, were as follows: Escherichia coli (21.4%), methicillin-susceptible Staphylococcus aureus (MSSA; 13.9%), Streptococcus pneumoniae (10.3%), Pseudomonas aeruginosa (7.1%), Klebsiella pneumoniae (6.0%), coagulase-negative staphylococci/Staphylococcus epidermidis (5.4%), methicillin-resistant S. aureus (MRSA; 5.1%), Haemophilus influenzae (4.1%), Enterococcus spp. (3.3%), Enterobacter cloacae (2.2%). MRSA comprised 27.0% (272/1,007) of all S. aureus isolates (genotypically, 68.8% of MRSA were health care associated [HA-MRSA] and 27.6% were community associated [CA-MRSA]). Extended-spectrum β-lactamase (ESBL)-producing E. coli occurred in 4.9% of E. coli isolates. The CTX-M type was the predominant ESBL, with CTX-M-15 the most prevalent genotype. MRSA demonstrated no resistance to ceftobiprole, daptomycin, linezolid, telavancin, tigecycline, or vancomycin (0.4% intermediate intermediate resistance). E. coli demonstrated no resistance to ertapenem, meropenem, or tigecycline. Resistance rates with P. aeruginosa were as follows: colistin (polymyxin E), 0.8%; amikacin, 3.5%; cefepime, 7.2%; gentamicin, 12.3%; fluoroquinolones, 19.0 to 24.1%; meropenem, 5.6%; piperacillin-tazobactam, 8.0%. A multidrug-resistant (MDR) phenotype occurred frequently in P. aeruginosa (5.9%) but uncommonly in E. coli (1.2%) and K. pneumoniae (0.9%). In conclusion, E. coli, S. aureus (MSSA and MRSA), P. aeruginosa, S. pneumoniae, K. pneumoniae, H. influenzae, and Enterococcus spp. are the most common isolates recovered from clinical specimens in Canadian hospitals. The prevalence of MRSA was 27.0% (of which genotypically 27.6% were CA-MRSA), while ESBL-producing E. coli occurred in 4.9% of isolates. An MDR phenotype was common in P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805395      PMCID: PMC2976152          DOI: 10.1128/AAC.00469-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Community-associated MRSA--resistance and virulence converge.

Authors:  Henry F Chambers
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

2.  Comparative genomics of Canadian epidemic lineages of methicillin-resistant Staphylococcus aureus.

Authors:  Sara Christianson; George R Golding; Jennifer Campbell; Michael R Mulvey
Journal:  J Clin Microbiol       Date:  2007-04-11       Impact factor: 5.948

3.  Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.

Authors:  Shawn R Lockhart; Murray A Abramson; Susan E Beekmann; Gale Gallagher; Stefan Riedel; Daniel J Diekema; John P Quinn; Gary V Doern
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

4.  Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007.

Authors:  L Blaettler; D Mertz; R Frei; L Elzi; A F Widmer; M Battegay; U Flückiger
Journal:  Infection       Date:  2009-12       Impact factor: 3.553

5.  Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.

Authors:  George G Zhanel; Mel DeCorby; Nancy Laing; Barb Weshnoweski; Ravi Vashisht; Franil Tailor; Kim A Nichol; Aleksandra Wierzbowski; Patricia J Baudry; James A Karlowsky; Philippe Lagacé-Wiens; Andrew Walkty; Melissa McCracken; Michael R Mulvey; Jack Johnson; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

6.  Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections.

Authors:  Johann D D Pitout; Daniel B Gregson; Lorraine Campbell; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

7.  First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.

Authors:  James S Lewis; Monica Herrera; Brian Wickes; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

8.  Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

Authors:  Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

9.  Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006).

Authors:  George G Zhanel; Mel Decorby; Kim A Nichol; Patricia J Baudry; James A Karlowsky; Philippe Rs Lagace-Wiens; Melissa McCracken; Michael R Mulvey; Daryl J Hoban
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-05       Impact factor: 2.471

10.  Community-associated methicillin-resistant Staphylococcus aureus, Canada.

Authors:  Michael R Mulvey; Laura MacDougall; Brenda Cholin; Greg Horsman; Melanie Fidyk; Shirley Woods
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

View more
  45 in total

1.  Modulation of the local neutrophil response by a novel hyaluronic acid-binding peptide reduces bacterial burden during staphylococcal wound infection.

Authors:  Jerry C Lee; Jennifer L Greenwich; George G Zhanel; Xiaobing Han; Andrew Cumming; Laura Saward; Rachel M McLoughlin
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

3.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Authors:  Heather J Adam; Nancy M Laing; C Richard King; Ben Lulashnyk; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 4.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

5.  Population-based surveillance for hypermucoviscosity Klebsiella pneumoniae causing community-acquired bacteremia in Calgary, Alberta.

Authors:  Gisele Peirano; Johann Dd Pitout; Kevin B Laupland; Bonnie Meatherall; Daniel B Gregson
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Evaluating state-specific antibiotic resistance measures derived from central line-associated bloodstream infections, national healthcare safety network, 2011.

Authors:  Minn M Soe; Jonathan R Edwards; Dawn M Sievert; Philip M Ricks; Shelley S Magill; Scott K Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2015-01       Impact factor: 3.254

7.  Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.

Authors:  Yen-Hsu Chen; Po-Liang Lu; Cheng-Hua Huang; Chun-Hsing Liao; Chin-Te Lu; Yin-Ching Chuang; Shih-Ming Tsao; Yao-Shen Chen; Yung-Ching Liu; Wei-Yu Chen; Tsrang-Neng Jang; Hsiu-Chen Lin; Chih-Ming Chen; Zhi-Yuan Shi; Sung-Ching Pan; Jia-Ling Yang; Hsiang-Chi Kung; Chun-Eng Liu; Yu-Jen Cheng; Jien-Wei Liu; Wu Sun; Lih-Shinn Wang; Wen-Chien Ko; Kwok-Woon Yu; Ping-Cherng Chiang; Ming-Hsun Lee; Chun-Ming Lee; Gwo-Jong Hsu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

8.  Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.

Authors:  Wang Liang; Yuan-cheng Chen; Yu-ran Cao; Xiao-fang Liu; Jun Huang; Jia-li Hu; Miao Zhao; Qing-lan Guo; Shu-jing Zhang; Xiao-jie Wu; De-mei Zhu; Ying-yuan Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

9.  Mutational activation of the AmgRS two-component system in aminoglycoside-resistant Pseudomonas aeruginosa.

Authors:  Calvin Ho-Fung Lau; Sebastien Fraud; Marcus Jones; Scott N Peterson; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Thomas Krahn; Christie Gilmour; Justin Tilak; Sebastien Fraud; Nicholas Kerr; Calvin Ho-Fung Lau; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.